Management
Christian Schaub, Co-founder, CEO and President
- Serial entrepreneur, business and start-up coach, keynote speaker
- M.Sc. in engineering, ETH Zurich
- Manages Redbiotec’s operations and growth to scientific leadership in bacterial and protein engineering
- Raised > CHF 20 mn capital for the company
- Headed the Pfizer deal (Redbiotec Spin-off Redvax sold to Pfizer)
- Led Redbiotec in closing deals with other pharma companies including Roche, Merck and Sanofi Pasteur
Dr. Corinne John, Co-founder, Executive Vice President
- Ph.D. in biochemistry, ETH Zurich
- Research at Harvard Medical School, USA
- Technology entrepreneurship degree from the executive school of the HSG
- W.A. de Vigier Prize Winner 2007
- Responsible for Human Resources and IP Strategy at Redbiotec
- Member of core M&A team leading the Pfizer deal
Dr. Lilli Stergiou, CSO
- Ph.D. in Molecular Biology and Genetics, Uni Zurich
- > 18 years of cross-disciplinary biomedical research experiences
- Joined Redbiotec in 2012. Appointed CSO in 2017
- Head of Herpes Immunotherapy Program
- Responsible for overseeing all research programs at Redbiotec
- Member of the core M&A team leading the Pfizer deal
- Founding member of the non-profit organization LSZYSN
Dr. Marina Studart, Senior Scientist, Project Leader – Gene Therapy
- Ph.D. in Biochemistry, ETH Zurich
- > 13 years of cross-disciplinary biomedical research experiences
- Joined Redbiotec in 2013
- Formerly responsible for the development of protein engineering platform prior to the Pfizer deal, and Co-Leader of the Oncology Program
- Currently Project Leader of Gene Therapy
Board of Directors
Christian Schaub, Chairman of the Board, CEO and co-founder
Dr. Corinne John, Board Member, co-founder
Dr. Michael Sidler, Board Member, Partner and co-founder of Redalpine Venture Partners AG
Dr. Michael Sidler joined the Redbiotec Board in 2009. Michael is a founding member of Redalpine Venture Partners AG, Zurich and is General Partner for the Redalpine Capital I fund (Luxemburg). Before becoming an Investor, he was responsible for Corporate Investments and M&A at Prionics, a Biotech Startup based in Schlieren. From 1998 to 2003, Michael worked for The Boston Consulting Group in Zurich and Toronto in different functions as a project manager. Michael is in various organizations, juries, and advisory boards for the development and support of start-up companies such as CTI Startup, Venturekick, CTI Invest, SECA, Technopark Zürich und Glatec. In addition to his engagement in Zurich, he is a partner at Intro International AS, a Norwegian company commercializing emerging technologies. He studied biology at the University of Zurich and received his PhD in 1998.
Dr. med. Hans-Peter Richard, Board Member, Investor
Dr. Hans-Peter Richard is a Medical Doctor based in Switzerland and a visiting lecturer at the Univ. of Bern. As an active private investor, he partners with a venture capital fund and manages direct investments in start-ups and fast-growing companies, with a strong focus on life sciences. A former board member of the Oettinger Davidoff Group, Dr. Richard is also a board member at several other companies.
Dr. Winfried Mayer, Board Member, Investor
Dr. Winfried Mayer was the former Head of Manufacturing at Roche Pharmaceuticals, and advisor to Chugai Pharmaceutical, Japan.